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http:WHAT THIS PAPER ADDS
The aim of this study was to perform a cost-analysis of a recommended but largely underutilized SET ﬁrst
treatment strategy in intermittent claudication (IC). Until now no study has been performed to investigate the
overall economic consequences of a nationwide SET ﬁrst approach (stepped care). As the study used a large
database (3.4 million people), daily practice is reﬂected well in the results. Implementation of a stepped care
treatment for patients with IC may lead to signiﬁcant savings of healthcare resources. These ﬁndings may be
generalizable to other European healthcare systems.Objectives: International guidelines recommend supervised exercise therapy (SET) as primary treatment for
intermittent claudication (IC). The aim of this study was to calculate treatment costs in patients with IC and to
estimate nationwide annual savings if a stepped care model (SCM, primary SET treatment followed by
revascularization in case of SET failure) was followed.
Methods: Invoice data of all patients with IC in 2009 were obtained from a Dutch health insurance company (3.4
millionmembers). Patientsweredivided into three groupsbasedon initial treatmentafterdiagnosis (t0).The SETgroup
received SET initiated at any time between 12months before and up to 3months after t0.The intervention group (INT)
underwent endovascular or open revascularization between t0 and tþ3 months.The third group (REST) received neither
SET nor any intervention. All peripheral arterial disease related invoices were recorded during 2 years and average
costs per patient were calculated. Savings following use of a SCM were calculated for three scenarios.
Results: Data on 4954 patients were analyzed. Initial treatment was SET (n ¼ 701, 14.1%), INT (n ¼ 1363, 27.5%),
or REST (n ¼ 2890, 58.3%). Within 2 years from t0, invasive revascularization in the SET group was performed in
45 patients (6.4%). Additional interventions (primary at other location and/or re-interventions) were performed
in 480 INT patients (35.2%). Some 431 REST patients received additional SET (n ¼ 299, 10.3%) or an intervention
(n ¼ 132, 4.5%). Mean total IC related costs per patient were V2,191, V9851 and V824 for SET, INT, and REST,
respectively. Based on a hypothetical worst, moderate, and best case scenario, some 3.8, 20.6, or 33.0 million
euros would have been saved per annum if SCM was implemented in the Dutch healthcare system.
Conclusion: Implementation of a SCM treatment for patients with IC may lead to signiﬁcant savings of health
care resources.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Recently governments, nongovernmental organizations,
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//dx.doi.org/10.1016/j.ejvs.2014.04.020(PAD) and to explore the best strategies for optimum
treatment and prevention of this disease.1 Although
treatment strategies for PAD are well described in inter-
national guidelines2e4 and advocate a multimodal
approach, including medication, lifestyle changes, and
symptomatic treatment, mentioning supervised exercise
therapy (SET) as the primary treatment option,3 the actual
availability of these SET programs worldwide is limited.5e9
There is a good availability of SET programs in the
Netherlands.10 However, a proven effective SET program
Exclusion criteria (n=870)
 -- insurance < 2 years
 -- vascular intervention in 2007 or 2008
Database of CZ (n=3.419.604 insured persons)
Eligible patients
n = 4954
Inclusion criteria (PAOD Fontaine II)
n = 5824
SET group
n = 701
INT group
n = 1363
REST group
n = 2890
tt t tt tt
Figure 1. Flow-chart of study population and classiﬁcation of subgroups. PAOD ¼ peripheral arterial occlusive disease. * straight line:
primary treatment; dashed line: secondary treatment.
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Figure 2. Referral for SET in the SET and REST group 12 months
prior and after diagnosis (t0).
424 H.J.P. Fokkenrood et al.(performed by physiotherapists trained in improving
cardiorespiratory health status as well as lifestyle factors
and medication compliance) is in many cases not fully
reimbursed.
This reimbursement issue originates from a contradictory
policy in the Dutch healthcare system. In the Netherlands,
healthcare insurance companies have an obligation to
accept everyone for basic healthcare insurance. The Dutch
government determines coverage of the standard insur-
ance. In the case of patients suffering from intermittent
claudication (IC) the government decided not to cover the
ﬁrst 20 treatment sessions of a SET program, which have to
be paid by the patient (either directly or through additional
insurance). From the 21st session onwards all additional
treatment sessions given in 1 year are covered by the basic
healthcare insurance. Medication (prescribed by a physi-
cian) and invasive vascular interventions are both included
in the standard package and fully reimbursed. As a conse-
quence SET is largely underutilized. Patients may receive
proven insufﬁcient and less cost-effective “go home and
walk” advice,11e14 or a vascular intervention as an alter-
native ﬁrst-line treatment strategy,5 which contradict
contemporary guidelines.
The advocated treatment strategy in the above-
mentioned guidelines could be incorporated into a so-
called “stepped care” model (SCM).5,15,16 This theoretical
approach strives to initially refer all IC patients to a SET
program and restrict revascularization to those who do not
respond to SET. Several cost-effectiveness analyses have
been performed supporting such a SET ﬁrst treatment
strategy.13,16e20 However, no study has been performed to
investigate the overall economic consequences of SCM
implementation nationwide. This study is a cost-analysis of
SCM implementation in the Dutch healthcare system. Costs
of IC treatment were calculated and compared with esti-
mated costs associated with three hypothetical scenarios of
nationwide SCM implementation.METHODS
Inclusion and exclusion
The 2009 database of CZ, a large Dutch healthcare insurance
company (n¼ 3,419,604 insured persons, approximately 21%
of theDutch population)was retrospectively analyzed. Insured
patients who had received an invoice related to the diagnosis
“PADFontaine 2” corresponding to IC complaints as diagnosed
by a vascular surgeon,were eligible for inclusion. Only patients
who had been insured for at least two consecutive years at CZ
were eligible, excluding crossover patients from other insur-
ance companies (possibly harboring an unknown 2-year his-
tory of PAD). To restrict the study to newly diagnosed IC
patients, all patients who underwent vascular interventions in
2007 or 2008were also excluded (Fig. 1). Data on co-morbidity
(diabetes mellitus, COPD, hypercholesterolemia, and heart
failure) were collected on the basis of prescribed medication.
Deﬁnition of IC subgroups
Patients meeting inclusion criteria were subdivided into
three groups based on the primary treatment initiated by
Table 1. Patient characteristics.
Group
SET INT REST p
Number of patients
(n - %)
701 (14) 1363 (27) 2890 (58)
Age (years) 69 65 68 <.001
Gender (% male) 57.3 64.8 58.9 <.001
Diabetes II (%) 6.9 7.0 8.2 ¼.24
CARA (%) 8.1 10.7 10.1 ¼.17
Hypercholesterolemia (%) 30.5 29.3 27.4 ¼.16
Congestive heart
failure (%)
9.6 8.7 12.0 <.01
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(t0 < t3 months) (Fig. 1).
 SET group: community-based SET started in the period
between 12 months prior to diagnosis up to 3 months
after the diagnosis of IC by a vascular surgeon (Fig. 2).
SET prior to diagnosis was possible in the situation of
referral by a patient’s general practitioner (GP) who had
already initiated SET.
 INT group: Any form of revascularization received within
3 months of diagnosis of IC by a vascular surgeon.
 REST group: Neither SET nor INT group inclusion criteria
were met (Fig. 2). It was assumed that these patients
received “go home and walk” advice or had no IC at all
(this contradictory “no IC in an IC population”
phenomenon is explained later).
Secondary treatment was deﬁned as a second intervention
(primary at another location and/or re-intervention or SET)
performed following primary treatment. This population
included patients with failure of primary treatment (re-inter-
vention), treatmentof the contralateral leg, or treatmentdelay
(treatment >t3 months). Differentiation between these groups
was not possible because of the nature of the database. It was
assumed that all patients received best medical treatment
(BMT) prescribed at the discretion of the physician.Costs of PAD treatment
A Fontaine classiﬁcation by a vascular surgeon is always
required for billing purposes in the Dutch healthcareTable 2. Revascularizations per group per anatomical section.
Primar
INT - g
Patients with intervention (n - %) 1363 (
Interventions per section
Invoices of Radiology dept. Bypass revascularization 8
Ao-Il, (one sided) 477
Ao-Il, (both sides) 219
FemPop (one sided) 313
FemPop (both sides) 27
Crural (one sided) 12
Invoices of Surgery dept. Endovasculara 9
Open 289
Open (both sides) 19
Ao-Il ¼ aorto-iliac; FemPop ¼ femoral-popliteal.
a Unspeciﬁed because of suboptimal registration.system. All claudication related invoices (by physician and
physiotherapists) for primary as well as secondary treat-
ment within 2 years follow-up of t0 were screened. The
majority of interventions in 2009 were performed by radi-
ologists, based on referral by vascular surgeons. Total costs
generated in the SET, INT, and REST groups were calculated
by adding all intervention costs for the group to which the
patient was initially allocated. Discrimination between a
secondary ipsilateral intervention and a primary contralat-
eral intervention was not possible because of the nature of
the database, aimed at costs registration. Mean total costs
(MTC) per patient per group were calculated. Expenditures
for medication use were not incorporated into the
calculations.Sensitivity-analysis of the REST group
Patients in the REST group were supposed to have received
walking advice. When a patient is referred to a vascular
surgeon for IC by a GP, a “PAD Fontaine 2” (synonymous to
IC) invoice is registered. However, if IC is subsequently ruled
out, the invoice is often not corrected to the proper invoice
“ruling out IC”. In a prospective analysis of 100 consecutive
patients, it was found that 30% of the GP referrals with
presumed IC in fact received an alternative, non-IC diag-
nosis (unpublished results). This phenomenon is not ﬁnan-
cially driven as reimbursement of a “rule out” invoice
appears V1.43 higher. This incorrect assignment may have
contaminated the composition of the REST group so it was
decided to exclude the REST group from the SCM cost-
analysis. However, a cost-analysis of the REST group was
performed in an additional sensitivity analysis (SA),
assuming 30% non-IC patients.Cost-analysis of nationwide adherence to a SCM
The costs of SCM were estimated for patients in the SET and
INT groups. Successful treatment guided by a SCM depends
on two critical success factors:
1. surgeon compliance (willingness) to refer each IC
patient to SET. Despite the fact that, according to
contemporary international guidelines, all patients withy treatment Secondary treatment
roup SET - group INT - group REST - group
100%) 45 (6.4%) 480 (35.2%) 132 (4.6%)
2 8 2
20 193 69
5 94 19
17 147 47
1 14 6
0 8 1
0 0 0
2 16 0
0 0 0
Table 3. SET sessions per group.
Primary treatment Secondary treatment
SET - group SET - group INT - group REST - group
Patients with SET (n - %) 701 (100%) NR 141 (10.3%) 299 (10.3%)
Number of SET sessions (mean  SD) 48 (42) NR 38 (35) 42 (47)
(minemax) (1e271) (1e176) (1e470)
NR ¼ not relevant.
426 H.J.P. Fokkenrood et al.IC initially should be referred for SET,2e4 this ratio was
hypothetically set to 80% (best), 50% (moderate), and
30% (worst) based on reimbursement issues,
appreciation of SET by vascular surgeons, and
preference (although evidence to do so is lacking) for
revascularization in certain cases.
2. patient motivation to participate in a SET program,
which largely depends on reimbursement issues (level
of compensation by the insurance company) as well as a
thorough understanding of the beneﬁts of a SET
program in comparison with an invasive intervention.
The latter is also strongly associated with the surgeon’s
knowledge regarding SET and the willingness to refer. To
allow for variation in patients’ willingness, this ratio was
arbitrarily set at 80% in case of full reimbursement for
all IC patients and optimal provision of information. At
the other end, 25% was chosen for the current levels of
reimbursement and information provision. These ratios
were also suggested from the results of a questionnaire
completed by a cohort of Dutch vascular surgeons.9
Combining doctor and patient factors in a comparative
model resulted in six hypothetical scenarios (80%e80%,
80%e25%, 50%e80%, 50%e25%, 30%e80%, and 30%e
25%). As both factors are interrelated (physicians will limit
SET referrals if patients drop out as a result of reimbursement
issues; conversely, physicians may not refer to SET because of
presumed preference for an intervention), only the three
most likely scenarios were considered: best (80%e80%),
moderate (50%e80%), and worst cases (30%e25%). In
addition, extrapolation for the Dutch population was per-
formed by multiplying total savings in the total group by a
factor of 4.94 (21% of the Dutch population is insured by CZ).Table 4. Mean total costs per patient per group during 2 years of
follow-up.
Group
SET
Mean
(minemax)
INT
Mean
(minemax)
REST
Mean
(minemax)
Physician based
invoices (V)
890
(99e14,428)
9,745
(2,515e50,173)
705
(99e17,935)
Physiotherapist
based invoices (V)
1,301
(28e7,187)
106
(28e4,914)
118
(28e12,886)
Mean total
costs (MTC)
V 2,191 V 9,851 V 824Data analysis
The insurance database was analyzed with SAS (SAS Insti-
tute Inc, New York, USA). Differences between categorical
variables were analyzed using a chi-square test. Statistical
analyses were performed using SPSS 20 software (SPSS Inc,
Chicago, USA). A two-sided p < .05 was considered statis-
tically signiﬁcant. Calculations of costs were made using
Excel 2011 (Microsoft Ofﬁce, Redmond, USA). Graphs were
created with Graphpad Prism 5 (GraphPad Software Inc, La
Jolla, USA).
RESULTS
Adherence to a SCM
A total of 5,824 patients with “PAD Fontaine 2” (IC) were
identiﬁed, of which 871 patients were excluded for reasonslisted in Fig. 1, leaving 4,954 IC patients for analysis. Four-
teen percent received SET, whereas 28% were primarily
treated with an invasive intervention (INT). The remaining
58% (n ¼ 2,890) did not receive any of these two treatment
regimens within 3 months of diagnosis (REST). Patient
characteristics of the three groups are shown in Table 1.
Signiﬁcant differences between groups were found with
respect to age, gender, and congestive heart failure. Pa-
tients in the INT group were younger, more often male, and
had congestive heart failure less often.
Primary and secondary treatments are depicted in
Tables 2 and 3. A total of 45 SET patients (6.4%) were
secondarily treated with an endovascular (n ¼ 43) or open
surgical (n ¼ 2) procedure (Table 2). In 1,363 INT patients,
1,055 endovascular (aortoiliac lesions: 696; femoro-
popliteal lesions: 340) and 308 open surgical procedures
were performed initially (Table 2). In 480 of these patients
(35.2%), an additional revascularization procedure (endo-
vascular: n ¼ 464; open: n ¼ 16) was performed within
2 years. In the REST group, 299 patients (10.3%)
were additionally treated with SET and 132 patients
(144 interventions, 4.6%) with an endovascular
revascularization.Costs of IC treatment
A wide range of costs was found regarding the physician-
based invoices. Bills ranged from minimums of V99 and
V2,515, to maximums of V14,428 and V50,173 for the SET
and INT groups, respectively. Total costs ranged from a
single visit at the patient outpatient clinic (V99) to a
bilateral open surgical revascularization. Mean costs of SET
declarations ranged from V28 to V7,187 in the SET group
to a maximum of V12,886 in the REST group as related to
the number of SET sessions (1 to 470 sessions; Table 3). The
MTC per patient in the SET group (V2,191) was almost ﬁve
times lower than a patient in the INT group (V9,851;
Table 4).
Table 5. Implementation of a stepped care model.
Scenario Groups Costs Savings
Cost-analysis Group Sensitivity analysis
SET (n) INT (n) INT to SETa Dutch
population
SET
(n)
REST
(n)
REST to SETa (INT to SET) þ
(REST to SET)a
Dutch
population
Current
(14% - NR%)
701 1,363 V 14,953,716 NR NR 701 2023 NR NR NR
Best case
(80%e80%)
1,573 491 V 8,276,594 V 6,677,121 V 32,992,834 1996 728 V 1,770,685 V 4,906,436 V 24,237,794
Moderate case
(50%e80%)
1,246 818 V 10,780,515 V 4,173,201 V 20,620,521 1510 1214 V 1,106,678 V 3,066,523 V 15,148,624
Worst case
(30%e25%)
803 1261 V 14,171,240 V 782,475 V 3,866,348 853 1871 V 207,502 V 574,973 V 2,840,367
NR ¼ not relevant.
a Based on CZ population.
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SCM
The effects on cost-savings of SCM with and without
sensitivity analysis (SA) are shown in Table 5. In the 2009
situation (14% SCM), the costs were 17.3 million euros. In
the hypothetical best-case scenario (80%e80%), 1,573 of
the 2,064 eligible patients would receive SET and 491 a
vascular intervention as initial treatment. Nationwide
implementation of such an 80%e80% SCM scenario would
result in annual savings of 33.0 million euros for the Dutch
population (Table 5). Implementation of the worst-case
scenario (30%e25%) would still reduce the yearly costs of
IC treatment by 3.9 million euros (Table 5). In the
sensitivity-analysis (SA), 2,023 of 2,890 patients remained in
the REST group (30% non-PAD exclusion), leaving 4,087
eligible IC patients for analysis. In the best-case scenario,
2,868 of these patients would receive SET, 491 a vascular
intervention and 728 walking advice. Savings would still be
reduced from 33.0 to 24.2 million with an 80%e80% SCM
implementation after SA (Table 5).DISCUSSION
Three international guidelines recommend SET as a ﬁrst line
treatment for patients with IC,2e4 supported by cost-
effectiveness analyses.13,16e20 Unfortunately, the availabil-
ity of SET programs in Europe is poor.10,21 Some consider
the substantial investment to achieve nationwide imple-
mentation of SET programs as a problem.13 These ﬁndings
imply that the initial investments to increase the availability
of SET in other countries may be beneﬁcial when guidelines
and therefore the SCM are followed. Despite the Dutch
having a well-organized community based SET network, this
should not be an excuse for other European countries but a
motivation to implement such a network. Furthermore,
SCM implementation effects and thus cost-savings may
even be larger as most foreign healthcare systems have low
penetration of (community-based) SET programs and thus a
potential lower threshold for invasive vascular in-
terventions. Moreover, the calculated savings of a SCM
approach in this study are in euros, while a reduction of
morbidity and mortality ratios might occur as well.Makris et al. claimed a 100% SET availability in the
Netherlands in 2012.10 The present study demonstrated
that a mere 14% of the IC patients were actually referred
for SET in 2009. The discrepancy between a relatively low
percentage of SET referrals and high availability of SET
programs might be explained by the combination of con-
ﬂicting reimbursement issues, increased patients’ and phy-
sicians’ enthusiasm for interventional procedures,16 and a
lack of appreciation of SET.9 The latter might be caused by
ambiguities in contemporary guidelines, which may be
responsible for invasive procedures being used too liberally
for IC caused by aortoiliac lesions as stated in the TASC.4 In
contrast, the NICE guideline suggests initial treatment of
this type of lesion with SET.3 Several large trials show
inconclusive results concerning treatment of aortoiliac le-
sions.22e25 In the present study, 28% of the patients
received a primary revascularization, of which 51% involved
aortoiliac lesions. More than half (58%) of the included
patients were assumed to have received walking advice. The
present study therefore clearly demonstrates that the TASC
II/NICE guidelines (restricting interventions to patients not
responding to SET) are largely neglected in Dutch practice. A
nationwide implementation of a SCM might tackle these
issues, and the anticipated cost-savings presented in this
study may facilitate current conﬂicting issues in
reimbursement.
Moreover, SCM may have substantial inﬂuence on IC
patients’ individual treatment strategy. It is known that
patients suffering from IC, regardless of the severity of the
walking restriction, have a range of other limitations.26
Initiating treatment with SET may provide awareness of
important functional restrictions in daily life other than
those caused by IC (e.g. COPD, congestive heart failure,
osteoarthritis, spinal stenosis, equilibrium disorders). So
following a SCM may prevent potentially futile vascular in-
terventions in multi-morbid patients who are limited by
more than just IC. Furthermore, once (successful) invasive
treatment has been performed, recurrent ipsilateral or
newly developed contralateral obstructions are likely to be
treated by invasive means too, contributing to a high re-
intervention ratio (35%) in the INT group. Surprisingly, this
was also found by others16 and is in line with reported
428 H.J.P. Fokkenrood et al.patency rates of endovascular revascularizations.27,28 Addi-
tionally, initiating a SET ﬁrst policy might not meet the as-
pirations of the contemporary articulate and demanding
patient, focused on a quick ﬁx for the problem. The present
ﬁndings suggest that a SCM, with a 3-month trial period
preceding invasive treatment, in which patients not
responding to SET are eligible for invasive treatment, might
decrease the number of interventions.
This study has limitations inherent to its retrospective
character. Some might argue that selection bias may have
inﬂuenced the results, as patients with more severe IC
complaints or with a speciﬁc atherosclerotic lesion may
preferentially have been treated by invasive means. How-
ever, all included patients had IC classiﬁed as Fontaine II,
and according to contemporary guidelines should have
received SET as a primary treatment.2e4 In addition, a
correcting factor was applied, in that the (best-case sce-
nario) calculations referral rate was set at an 80% ratio
(instead of the guidelines’ 100%), permitting the remaining
20% to be treated based on the personal preference of the
patient or vascular surgeon.
Furthermore, this study showed differences in patient
characteristics between groups (age, gender, and CHF).
Unfortunately, it was not possible to adjust the analyses for
these covariates because of privacy limitations of the in-
surance company database. The ﬁndings reveal that young
males were treated more frequently by revascularization
compared with older patients or females. This phenomenon
might reﬂect assumptions and indirect evidence suggesting
that invasive treatment should be preferred in a working
age population as recovery is deemed quicker. The same
might be the case in the assumption that as endovascular
treatment for aortoiliac lesions is more durable compared
with femoropopliteal lesions, this warrants an intervention
in aortoiliac lesions.27 However, as far as the authors know,
no evidence substantiates such an invasive ﬁrst line treat-
ment for certain IC subgroups.
A formal cost-effectiveness study could not be performed
as the insurance company’s database lacks data on treat-
ment effect or outcome. Furthermore, costs related to an
intervention of the ipsi- or contralateral leg could not be
identiﬁed which may have biased total costs of the INT
group. However, this limitation is relative as walking exer-
cise pertains to both legs.Future perspectives
Reimbursement issues in the Dutch healthcare system
remain an issue. Optimization of a SCM depends on political
decision-making and awareness of the functional and
ﬁnancial advantages of SET by healthcare insurers. The
impact of a SCM implementation on Dutch as well as Eu-
ropean society should be subject to future research.CONCLUSION
In addition to the solid evidence supporting SET as ﬁrst line
treatment for patients with IC, introduction of andadherence to a SCM may lead to signiﬁcant savings of
healthcare resources associated with the treatment of pa-
tients with IC.FUNDING
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